273 related articles for article (PubMed ID: 8804920)
1. Critical reevaluation of spiperone and benzamide binding to dopamine D2 receptors: evidence for identical binding sites.
Malmberg A; Jerning E; Mohell N
Eur J Pharmacol; 1996 May; 303(1-2):123-8. PubMed ID: 8804920
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and binding properties of the fluorinated substituted benzamide [3H]NCQ 115, a new selective dopamine D2 receptor ligand.
Hall H; Högberg T; Halldin C; Bengtsson S; Wedel I
Eur J Pharmacol; 1991 Aug; 201(1):1-10. PubMed ID: 1686586
[TBL] [Abstract][Full Text] [Related]
3. In vitro receptor binding characteristics of the new dopamine D2 antagonist [125I]NCQ-298: methodological considerations of high affinity binding.
Jerning E; Malmberg A; Mohell N
J Recept Signal Transduct Res; 1995; 15(1-4):503-15. PubMed ID: 8903960
[TBL] [Abstract][Full Text] [Related]
4. [3H]nemonapride and [3H]spiperone label equivalent numbers of D2 and D3 dopamine receptors in a range of tissues and under different conditions.
Vile JM; D'Souza UM; Strange PG
J Neurochem; 1995 Feb; 64(2):940-3. PubMed ID: 7830089
[TBL] [Abstract][Full Text] [Related]
5. Dopamine receptor subtypes: differential regulation after 8 months treatment with antipsychotic drugs.
Florijn WJ; Tarazi FI; Creese I
J Pharmacol Exp Ther; 1997 Feb; 280(2):561-9. PubMed ID: 9023264
[TBL] [Abstract][Full Text] [Related]
6. Comparisons between the in vitro binding of two substituted benzamides and two butyrophenones to dopamine-D2 receptors in the rat striatum.
Hall H; Wedel I
Acta Pharmacol Toxicol (Copenh); 1986 May; 58(5):368-73. PubMed ID: 2943136
[TBL] [Abstract][Full Text] [Related]
7. Binding characteristics of remoxipride and its metabolites to dopamine D2 and D3 receptors.
Mohell N; Sällemark M; Rosqvist S; Malmberg A; Högberg T; Jackson DM
Eur J Pharmacol; 1993 Jul; 238(1):121-5. PubMed ID: 8405075
[TBL] [Abstract][Full Text] [Related]
8. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human brain positron emission tomography.
Seeman P; Guan HC; Civelli O; Van Tol HH; Sunahara RK; Niznik HB
Eur J Pharmacol; 1992 Oct; 227(2):139-46. PubMed ID: 1358662
[TBL] [Abstract][Full Text] [Related]
9. High affinity dopamine D2 receptor radioligands. 2. [125I]epidepride, a potent and specific radioligand for the characterization of striatal and extrastriatal dopamine D2 receptors.
Kessler RM; Ansari MS; Schmidt DE; de Paulis T; Clanton JA; Innis R; al-Tikriti M; Manning RG; Gillespie D
Life Sci; 1991; 49(8):617-28. PubMed ID: 1830917
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of [3H]nemonapride and [3H]spiperone binding on human dopamine D4 receptors.
Hidaka K; Matsumoto M; Tada S; Tasaki Y; Yamaguchi T
Neurosci Lett; 1995 Feb; 186(2-3):145-8. PubMed ID: 7777184
[TBL] [Abstract][Full Text] [Related]
11. Distinct binding patterns of [3H]raclopride and [3H]spiperone at dopamine D2 receptors in vivo in rat brain. Implications for pet studies.
Bischoff S; Gunst F
J Recept Signal Transduct Res; 1997; 17(1-3):419-31. PubMed ID: 9029505
[TBL] [Abstract][Full Text] [Related]
12. (-)S amisulpride binds with high affinity to cloned dopamine D(3) and D(2) receptors.
Castelli MP; Mocci I; Sanna AM; Gessa GL; Pani L
Eur J Pharmacol; 2001 Dec; 432(2-3):143-7. PubMed ID: 11740949
[TBL] [Abstract][Full Text] [Related]
13. Potential antipsychotic agents. 9. Synthesis and stereoselective dopamine D-2 receptor blockade of a potent class of substituted (R)-N-[(1-benzyl-2-pyrrolidinyl)methyl]benzamides. Relations to other side chain congeners.
Högberg T; Ström P; de Paulis T; Stensland B; Csöregh I; Lundin K; Hall H; Ogren SO
J Med Chem; 1991 Mar; 34(3):948-55. PubMed ID: 1672158
[TBL] [Abstract][Full Text] [Related]
14. Dopamine D2 receptors selectively labeled by a benzamide neuroleptic: [3H]-YM-09151-2.
Niznik HB; Grigoriadis DE; Pri-Bar I; Buchman O; Seeman P
Naunyn Schmiedebergs Arch Pharmacol; 1985 Jun; 329(4):333-43. PubMed ID: 2863760
[TBL] [Abstract][Full Text] [Related]
15. [125]I-spectramide: a novel benzamide displaying potent and selective effects at the D2 dopamine receptor.
Sánchez-Roa PM; Grigoriadis DE; Wilson AA; Sharkey J; Dannals RF; Villemagne VL; Wong DF; Wagner HN; Kuhar MJ
Life Sci; 1989; 45(19):1821-9. PubMed ID: 2531826
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 receptors in the anterior pituitary: a single population without reciprocal antagonist/agonist states.
George SR; Watanabe M; Seeman P
J Neurochem; 1985 Apr; 44(4):1168-77. PubMed ID: 2579204
[TBL] [Abstract][Full Text] [Related]
17. Binding of 3H-spiperone and 3H-(-)-sulpiride to dopamine D2 receptors in rat striatal membranes: methodological considerations and demonstration of the identical nature of the binding sites for the two ligands.
Urwyler S; Coward D
Naunyn Schmiedebergs Arch Pharmacol; 1987 Feb; 335(2):115-22. PubMed ID: 2951601
[TBL] [Abstract][Full Text] [Related]
18. Comparison of [3H]nemonapride and [3H]spiperone binding to D2(long) dopamine receptors.
Vile JM; Strange PG
Biochem Soc Trans; 1995 Feb; 23(1):90S. PubMed ID: 7538954
[No Abstract] [Full Text] [Related]
19. Differential regulation of dopamine receptors after chronic typical and atypical antipsychotic drug treatment.
Tarazi FI; Florijn WJ; Creese I
Neuroscience; 1997 Jun; 78(4):985-96. PubMed ID: 9174067
[TBL] [Abstract][Full Text] [Related]
20. NCQ 298, a new selective iodinated salicylamide ligand for the labelling of dopamine D2 receptors.
Hall H; Högberg T; Halldin C; Köhler C; Ström P; Ross SB; Larsson SA; Farde L
Psychopharmacology (Berl); 1991; 103(1):6-18. PubMed ID: 1672460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
